Latest Period
Q1 2026
Security Snapshot
IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) Institutional Ownership
CUSIP: 46333X108
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
223
Shares (Excl. Options)
160,324,992
Price
$3.51
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Class A Common Stock
- Symbol
- IRWD on Nasdaq
- Shares outstanding
- 163,317,295
- Price per share
- $4.07
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 160,324,992
- Total reported value
- $562,668,116
- % of total 13F portfolios
- 0%
- Share change
- +7,352,662
- Value change
- +$26,626,724
- Number of holders
- 223
- Price from insider filings
- $4.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- IRWD - IRONWOOD PHARMACEUTICALS INC - Class A Common Stock is tracked under CUSIP 46333X108.
- 223 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 196 to 223 between Q4 2025 and Q1 2026.
- Reported value moved from $519,062,006 to $562,668,116.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 223 institutions filings for Q1 2026.
Security key
46333X108
Latest holder period
Q1 2026
13F holders
223
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
IRWD full holder history
IRONWOOD PHARMACEUTICALS INC SEC filings
IRONWOOD PHARMACEUTICALS INC company facts
IRONWOOD PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 46333X108:
Significant Owners of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 10% | +2.1% | $10,855,426 | +$338,999 | 16,202,129 | +3.2% | The Vanguard Group | 30 Jun 2025 |
| ARMISTICE CAPITAL, LLC | 9.8% | +17% | $82,368,500 | +$11,950,500 | 16,025,000 | +17% | Armistice Capital, LLC | 31 Dec 2025 |
| BlackRock, Inc. | 7.1% | $9,930,271 | 11,284,399 | BlackRock, Inc. | 28 Feb 2025 | |||
| BANK OF AMERICA CORP /DE/ | 6.1% | -19% | $34,967,866 | -$7,103,931 | 9,962,355 | -17% | BANK OF AMERICA CORP /DE/ | 31 Mar 2026 |
| Sarissa Capital Management LP | 5.8% | $31,735,012 | 9,444,944 | Alexander J. Denner | 17 Mar 2026 | |||
| RENAISSANCE TECHNOLOGIES LLC | 5.4% | $7,565,534 | 8,597,198 | Renaissance Technologies LLC | 15 May 2024 | |||
| STATE STREET CORP | 2.2% | -60% | $3,078,494 | -$4,250,865 | 3,498,289 | -58% | STATE STREET CORPORATION | 31 Mar 2025 |
| BARCLAYS PLC | 2% | -70% | $4,149,704 | -$10,435,649 | 3,167,713 | -72% | Barclays PLC | 30 Sep 2025 |
| Pacer Advisors, Inc. | 1.1% | -89% | $1,574,406 | -$8,748,672 | 1,789,098 | -85% | Pacer US Small Cap Cash Cows ETF | 31 Mar 2025 |
As of 31 Mar 2026, 223 institutional investors reported holding 160,324,992 shares of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD). This represents 98% of the company’s total 163,317,295 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.2% | 15,028,000 | -6.2% | 1.7% | $52,748,280 |
| BlackRock, Inc. | 8.2% | 13,362,930 | +4.5% | 0% | $46,903,884 |
| Sarissa Capital Management LP | 5.6% | 9,188,635 | -42% | 20% | $32,252,109 |
| BANK OF AMERICA CORP /DE/ | 5.3% | 8,682,907 | -25% | 0% | $30,477,004 |
| RENAISSANCE TECHNOLOGIES LLC | 4.9% | 8,061,073 | -1.8% | 0.04% | $28,294,366 |
| AQR CAPITAL MANAGEMENT LLC | 4.6% | 7,535,080 | +60% | 0.01% | $26,448,131 |
| STATE STREET CORP | 4.6% | 7,456,944 | +69% | 0% | $26,173,873 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1% | 6,682,037 | 0% | 0% | $23,453,950 |
| ACADIAN ASSET MANAGEMENT LLC | 4% | 6,577,272 | +1.8% | 0.03% | $23,065,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 6,097,454 | 0% | 0% | $21,402,064 |
| TWO SIGMA INVESTMENTS, LP | 3.6% | 5,848,276 | +105% | 0.02% | $20,527,449 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.9% | 4,737,857 | -4.8% | 0% | $16,629,878 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8% | 4,543,522 | +25% | 0% | $15,950,694 |
| MARSHALL WACE, LLP | 2.8% | 4,525,064 | +2.3% | 0.02% | $15,882,975 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2.2% | 3,632,477 | +32% | 0.05% | $12,749,994 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.1% | 3,397,242 | +724% | 0.01% | $11,924,319 |
| FEDERATED HERMES, INC. | 2.1% | 3,348,806 | +0.92% | 0.02% | $11,754,309 |
| GOLDMAN SACHS GROUP INC | 1.6% | 2,690,634 | +111% | 0% | $9,444,125 |
| DIMENSIONAL FUND ADVISORS LP | 1.3% | 2,082,055 | +529% | 0% | $7,306,566 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.1% | 1,835,424 | -7.8% | 0.01% | $6,442,338 |
| Qube Research & Technologies Ltd | 0.97% | 1,590,081 | -5.4% | 0.01% | $5,581,184 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.9% | 1,472,157 | +228% | 0.01% | $5,167,271 |
| NORTHERN TRUST CORP | 0.78% | 1,265,842 | +2.6% | 0% | $4,443,105 |
| Hillsdale Investment Management Inc. | 0.76% | 1,236,628 | +6.9% | 0.12% | $4,340,565 |
| DEUTSCHE BANK AG\ | 0.69% | 1,124,989 | +1.4% | 0% | $3,948,711 |
Institutional Holders of IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 160,324,992 | $562,668,116 | +$26,626,724 | $3.51 | 223 |
| 2025 Q4 | 153,978,212 | $519,062,006 | +$36,443,345 | $3.37 | 196 |
| 2025 Q3 | 148,541,007 | $194,617,095 | +$6,212,194 | $1.31 | 160 |
| 2025 Q2 | 146,448,573 | $105,056,220 | -$19,990,203 | $0.72 | 151 |
| 2025 Q1 | 155,587,802 | $228,692,691 | -$26,001,186 | $1.47 | 200 |
| 2024 Q4 | 164,213,918 | $727,463,387 | +$1,737,232 | $4.43 | 222 |
| 2024 Q3 | 163,472,233 | $673,496,034 | -$53,233,700 | $4.12 | 218 |
| 2024 Q2 | 171,468,668 | $1,117,746,593 | -$10,390,681 | $6.52 | 226 |
| 2024 Q1 | 172,118,333 | $1,499,071,284 | +$34,523,403 | $8.71 | 259 |
| 2023 Q4 | 164,989,974 | $1,887,503,875 | +$27,460,717 | $11.44 | 248 |
| 2023 Q3 | 162,344,641 | $1,563,374,016 | -$47,770,085 | $9.63 | 248 |
| 2023 Q2 | 166,095,520 | $1,767,006,761 | +$4,551,974 | $10.64 | 249 |
| 2023 Q1 | 165,499,147 | $1,741,215,310 | -$25,432,141 | $10.52 | 253 |
| 2022 Q4 | 167,942,496 | $2,080,711,382 | -$11,969,237 | $12.39 | 248 |
| 2022 Q3 | 169,832,029 | $1,759,668,119 | -$66,873,989 | $10.36 | 234 |
| 2022 Q2 | 175,222,861 | $2,020,512,624 | +$105,001,683 | $11.53 | 229 |
| 2022 Q1 | 166,602,554 | $2,094,673,928 | -$62,666,606 | $12.58 | 205 |
| 2021 Q4 | 171,908,670 | $2,002,842,425 | -$78,175,850 | $11.66 | 206 |
| 2021 Q3 | 177,433,352 | $2,315,405,743 | +$38,243,173 | $13.06 | 216 |
| 2021 Q2 | 174,523,300 | $2,245,931,885 | +$54,432,994 | $12.87 | 200 |
| 2021 Q1 | 171,145,457 | $1,913,286,723 | -$10,293,889 | $11.18 | 202 |
| 2020 Q4 | 171,628,514 | $1,954,636,964 | -$289,602 | $11.39 | 191 |
| 2020 Q3 | 179,160,124 | $1,611,634,384 | -$60,043,147 | $9.00 | 183 |
| 2020 Q2 | 178,119,023 | $1,838,125,889 | +$1,165,854 | $10.32 | 196 |
| 2020 Q1 | 178,568,993 | $1,801,785,844 | +$4,161,742 | $10.09 | 186 |
| 2019 Q4 | 177,455,640 | $2,362,005,410 | +$49,445,414 | $13.31 | 191 |
| 2019 Q3 | 173,764,399 | $1,491,782,455 | +$101,224,965 | $8.58 | 156 |
| 2019 Q2 | 161,310,235 | $1,764,640,729 | +$57,814,939 | $10.94 | 148 |
| 2019 Q1 | 154,995,090 | $2,094,495,667 | +$91,122,285 | $13.53 | 150 |
| 2018 Q4 | 149,504,826 | $1,548,336,251 | -$71,151,637 | $10.36 | 141 |
| 2018 Q3 | 144,665,764 | $2,670,486,249 | -$61,027,521 | $18.46 | 149 |
| 2018 Q2 | 148,813,231 | $2,845,437,392 | -$59,848,588 | $19.12 | 145 |
| 2018 Q1 | 152,306,846 | $2,350,190,262 | -$1,008,869 | $15.43 | 145 |
| 2017 Q4 | 152,837,109 | $2,291,153,384 | -$72,488,750 | $14.99 | 157 |
| 2017 Q3 | 157,184,610 | $2,478,904,357 | +$150,604,537 | $15.77 | 145 |
| 2017 Q2 | 147,586,787 | $2,784,285,643 | +$174,107,575 | $18.88 | 165 |
| 2017 Q1 | 146,394,957 | $2,497,507,218 | +$313,109,692 | $17.06 | 158 |
| 2016 Q4 | 140,093,291 | $2,142,057,976 | +$7,058,282 | $15.29 | 159 |
| 2016 Q3 | 138,112,999 | $2,188,767,596 | +$19,185,042 | $15.88 | 150 |
| 2016 Q2 | 137,183,569 | $1,793,474,568 | -$46,641,420 | $13.07 | 142 |
| 2016 Q1 | 141,086,992 | $1,542,611,000 | +$6,575,341 | $10.94 | 133 |
| 2015 Q4 | 140,004,988 | $1,623,135,302 | -$10,046,894 | $11.59 | 133 |
| 2015 Q3 | 141,087,024 | $1,469,578,326 | -$31,592,141 | $10.42 | 129 |
| 2015 Q2 | 143,581,013 | $1,730,907,955 | +$111,334,758 | $12.06 | 137 |
| 2015 Q1 | 133,635,220 | $2,138,495,680 | +$8,239,322 | $16.00 | 142 |
| 2014 Q4 | 133,616,046 | $2,046,265,589 | +$20,104,400 | $15.32 | 129 |
| 2014 Q3 | 131,914,423 | $1,709,440,539 | +$65,713,386 | $12.96 | 138 |
| 2014 Q2 | 126,250,568 | $1,934,608,469 | -$76,713,665 | $15.33 | 136 |
| 2014 Q1 | 131,861,633 | $1,624,155,433 | +$224,093,523 | $12.32 | 135 |